retatrutide fatty liver study STUDY: Novel “Triagonist” Resolved Steatosis in Over 85% of Patients with MASLD and Obesity Researchers are reporting promising results

My Google Meet consultation was the most information-heavy appointment Ive had at any GLP-1 clinic

We have convenient locations to serve you in Modesto, CA, and Lodi, CA

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease

In the Phase III NefIgArd trial, patients treated with Tarpeyo saw significantly better kidney function, as measured by the estimated glomerular filtration rate (eGFR) versus placebo after nine months on the drug and 15 months of follow-up

Researchers have also noted that 70% of diabetes patients discontinue GLP-1 receptor agonist treatment within two years, limiting the long-term efficacy of these drugs

The possible mechanisms of weight loss caused by GLP-1R agonists is shown in Figure 1